Abstract
In September 2003, daptomycin (Cubicin; Cubist Pharmaceuticals) — the first member of a new class of antibiotics — was approved by the US FDA for the treatment of infections caused by Gram-positive bacteria. Will its ability to treat infections resistant to many current antibiotics lead to significant market success?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Stepwise Evolution Improves Identification of Diverse Peptides Binding to a Protein Target
Scientific Reports Open Access 21 September 2017
-
Endophytes as Producers of Peptides: An Overview About the Recently Discovered Peptides from Endophytic Microbes
Natural Products and Bioprospecting Open Access 10 September 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Coates, A. et al. The future challenges facing the development of new antimicrobial drugs. Nature Rev. Drug Discov. 1, 895–910 (2002).
Walsh, C. Where will new antibiotics come from? Nature Rev. Microbiol. 1, 65–69 (2003).
Lowy, F. D. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. 111, 1265–1273 (2003).
Tally, F. P. & DeBruin, M. F. Development of daptomycin for Gram-positive infections. J. Antimicrob. Chemother. 46, 523–526 (2000).
FDA Drug Approvals List [online] (cited 29 October 2003). <http://www.fda.gov/cder/foi/label/2003/21572_cubicin_lbl.pdf> (2003).
Debono, M. et al. Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J. Antibiot. (Tokyo) 41, 1093–1105 (1988).
Fuchs, P. C. et al. In vitro bactericidal acitivity of daptomycin against staphylococci. J. Antimicrob. Chemother. 49, 467–470 (2002).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Raja, A., LaBonte, J., Lebbos, J. et al. Daptomycin. Nat Rev Drug Discov 2, 943–944 (2003). https://doi.org/10.1038/nrd1258
Issue Date:
DOI: https://doi.org/10.1038/nrd1258
This article is cited by
-
Chemoenzymatic approaches for exploring structure–activity relationship studies of bioactive natural products
Nature Synthesis (2023)
-
Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system
International Journal of Clinical Pharmacy (2022)
-
Cell permeability, β-lactamase activity, and transport contribute to high level of resistance to ampicillin in Lysobacter enzymogenes
Applied Microbiology and Biotechnology (2020)
-
Stepwise Evolution Improves Identification of Diverse Peptides Binding to a Protein Target
Scientific Reports (2017)
-
Daptomycin antibiotic production processes in fed-batch fermentation by Streptomyces roseosporus NRRL11379 with precursor effect and medium optimization
Bioprocess and Biosystems Engineering (2014)